Methyl 5-(2-Pyrazinyl)isoxazole-3-carboxylate
|
- $60 - $428
- Product name: Methyl 5-(2-Pyrazinyl)isoxazole-3-carboxylate
- CAS: 1375064-69-9
- MF: C9H7N3O3
- MW: 205.17
- EINECS:
- MDL Number:MFCD22192340
- Synonyms:Methyl 5-(2-Pyrazinyl)isoxazole-3-carboxylate;3-Isoxazolecarboxylic acid, 5-(2-pyrazinyl)-, methyl ester;Methyl 5-(pyrazin-2-yl)isoxazole-3-carboxylate
4 prices
Selected condition：
Brand
- AK Scientific
- Chemenu
- Crysdot
- TRC
Package
- 100mg
- 250mg
- 5g
- ManufacturerAK Scientific
- Product number7088AJ
- Product descriptionMethyl5-(2-pyrazinyl)isoxazole-3-carboxylate
- Packaging250mg
- Price$158
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM320424
- Product descriptionmethyl5-(pyrazin-2-yl)isoxazole-3-carboxylate 95%
- Packaging5g
- Price$400
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11269656
- Product descriptionMETHYL5-(2-PYRAZINYL)ISOXAZOLE-3-CARBOXYLATE 95+%
- Packaging5g
- Price$428
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberM221908
- Product descriptionMethyl5-(2-Pyrazinyl)isoxazole-3-carboxylate
- Packaging100mg
- Price$60
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AK Scientific | 7088AJ | Methyl5-(2-pyrazinyl)isoxazole-3-carboxylate | 250mg | $158 | 2021-12-16 | Buy |
| Chemenu | CM320424 | methyl5-(pyrazin-2-yl)isoxazole-3-carboxylate 95% | 5g | $400 | 2021-12-16 | Buy |
| Crysdot | CD11269656 | METHYL5-(2-PYRAZINYL)ISOXAZOLE-3-CARBOXYLATE 95+% | 5g | $428 | 2021-12-16 | Buy |
| TRC | M221908 | Methyl5-(2-Pyrazinyl)isoxazole-3-carboxylate | 100mg | $60 | 2021-12-16 | Buy |
Properties
Boiling point :396.6±42.0 °C(Predicted)
Density :1.323±0.06 g/cm3(Predicted)
pka :-0.60±0.10(Predicted)
Density :1.323±0.06 g/cm3(Predicted)
pka :-0.60±0.10(Predicted)
Safety Information
| Symbol(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||
| Hazard statements: |
|
||||||||||||||
| Precautionary statements: |
|